Primary Sjögren Syndrome

Primary Sjögren's Syndrome Clinical Trial

— NeuroSenSS  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01989819
• Other study ID #: I10 023
• Status: Completed
• Start date: September 2012
• Est. completion date: June 2017

Study information

• Verified date: June 2016
• Source: University Hospital, Limoges
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Primary Sjögren syndrome (pSS) is an inflammatory, autoimmune, multiorgan disease often involving the central and peripheral nervous systems. Fifteen to twenty percent of patients with the primary Sjögren's syndrome have neurological complications involving the peripheral nervous system. Although some patients have large fiber neuropathy, around forty percent of patients with Sjögren's syndrome experience neuropathic pain with normal electrodiagnostic studies. Although these patients may be diagnosed with fibromyalgia or depressive symptoms, some have been shown to have small fiber neuropathy (SFN). A recent study proved that more than 90% of pSS patients with such neuropathic pain have SFN {Fauchais, 2010 #188}.

The aim of this study will be to investigate the occurrence of small fiber neuropathy in patients with pSS and neuropathic pain with normal electromyographic studies and to determine the existence of a conjoint local inflammatory process mediated by cellular, cytokinic or auto-antibody response. Quantification of epidermal nerve fiber density after skin biopsy is a valuable tool to diagnose small fiber neuropathy and the method has been widely validated. A skin biopsy will be performed in patients and control and will allow quantification of small fiber density in skin sample along with measurement of sweat gland innervation. Moreover, pathophysiological studies will be carried on in order to evaluate the causal relationship between cellular and humoral inflammation and small fiberneuropathy.

Recent studies have pointed out the inconstant efficacy of both corticosteroid and immunosuppressive drugs in pSS-related SFN. Dissecting the molecular mechanisms of small fiber neuropathy in these patients may help designing new therapeutic strategies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: June 2017
• Est. primary completion date: September 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with pSS according to revised European criteria and exhibiting neuropathic pain without any electromyographic abnormality will be included (Group I).

• Age of entry into the study = 18 yrs (both groups).

• Affiliated or profit patient of a social security system (both groups).

• Informed consent signed up (both groups).

Exclusion Criteria:

• Chronic alcoholism

• Type I or type II diabetes

• Peripheral neuropathy unrelated to pSS complications

• Coagulation disease

• Previous allergy to xylocaine, lidocaine, prilocaine or ricin oil

• Porphyria, methemoglobinemia

• Patients under measure of maintenance of justice.

• Patients unable to understand or to participate to the study.

• Child and major patients making the object of a measure of lawful protection.

• Patients deprived of freedom.

• Pregnant, nursing women.

• Participation in biomedical research within one month prior to inclusion.

Related Conditions & MeSH terms

• Primary Sjögren's Syndrome
• Sjogren's Syndrome
• Syndrome

Intervention

Other:
• skin biopsy

Locations

Country	Name	City	State
France	CH d'Albi	Albi
France	CHU Bordeaux	Bordeaux
France	CH de Brive	Brive la Gaillarde
France	CHU de Lille	Lille
France	University Hospital, Limoges	Limoges
France	CH de Rodez	Rodez
France	CHU Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the cutaneous lymphocytic infiltration		1 year
Secondary	Cutaneous infiltration T, B and Th17		1 year